ArticleJournal of assisted reproduction and genetics2021
Correction to: Dehydroepiandrosterone sulphate (DHEAS) concentrations stringently regulate fertilization, embryo development and IVF outcomes: are we looking at a potentially compelling 'oocyte-related factor' in oocyte activation?
Article in Journal of assisted reproduction and genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabonomic analysis of follicular fluid in patients with diminished ovarian reserve.Frontiers in endocrinology · 2023Article
Corrections and comments
- Erratum for
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeErratic oocyte-activation affects fertilization and embryo development. Dehydro-epiandrosterone sulphate (DHEAS) is present in theca/cumulus-granulosa cells, regulates the same calcium-pumps that cause calcium-oscillations in mice and its levels are altered in women with no or low fertilization rates. Yet no study has explored correlation of DHEAS with oocyte-activation. We proposed to implicate DHEAS as an oocyte-related factor in oocyte-activation by demonstrating that rectification of deviated (both lower/and higher than normal) DHEAS concentrations to normal post-treatment improves fertilization, embryo development rates.
methodProspective Closed-Cohort. Recruited n = 750 (150 women/subgroup) in previously classified Low(A), Average/Control(B), High(C) D3-serum DHEAS groups. 50% women in both A and C groups received 3-months exposure to oral DHEAS and Metformin respectively. Also measured Follicular-fluid DHEAS levels. Compared embryologic, clinical outcomes: DHEAS untreated (A1) vs. treated (A2); metformin untreated (C1) vs. treated (C2) and A1/A2/C1/C2 against normal-control-B group. Also compared serum vs. FF-group results.
resultsSignificantly improved embryologic, clinical parameters in treated A2/C2 compared to untreated A1/C1 subgroups respectively. Post-treated improved parameters in A2/C2 were comparable with, whereas untreated A1/C1 sub-groups had significantly lower values than, normal-control B-group. Parameters differed significantly between Low, Medium, High FF-DHEAS groups. Results in serum vs. FF: A1 vs. LowFF, C1 vs. HighFF and A2/C2/B vs. MediumFF were comparable. Odds of fertilization, live-births increased in post-treatment A2/C2 subgroups. Fertilization rates strongly correlated with FF-DHEAS.
conclusionRectification of deviated DHEAS levels post-treatment significantly improves outcomes, comparable with those exhibited by normal-control DHEAS thresholds. DHEAS is the most promising endogenous oocyte-related factor influencing embryologic, clinical IVF outcomes possibly by affecting oocyte-activation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.